Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies.

Neurotherapeutics · 2022 · PMC9294130 · PMID 35084720

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

The benefit, based on our experience, has been overall minimal and short-lived, while the doses required are quite significant for routine use. v) Supportive therapies.

also in 5,695 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.